Operational Feasibility of Appropriate Plasmodium Vivax Radical Cure with Tafenoquine or Primaquine after Quantitative G6PD Testing in Brazil (TRuST)

This is an observational real-world study. 

Primary objective:
To investigate whether Plasmodium vivax patients ≥16 years are treated with tafenoquine (TQ) in accordance with the appropriate level of glucose-6-phosphate dehydrogenase (G6PD) enzyme activity.

Secondary objectives:

  • To investigate whether P. vivax patients ≥6 months are treated with primaquine (PQ) in accordance with the appropriate level of G6PD enzyme activity;
  • To describe the characteristics of patients treated with TQ or PQ;
  • To measure frequency of drug-induced acute haemolytic anemia (AHA) and hospitalization due to drug-induced AHA.

Further information

For more information on the TRuST study please see our TRuST study page.